gallium-ga-68-dotatate and pasireotide

gallium-ga-68-dotatate has been researched along with pasireotide* in 1 studies

Other Studies

1 other study(ies) available for gallium-ga-68-dotatate and pasireotide

ArticleYear
Somatostatin receptor imaging-guided pasireotide therapy in medullary thyroid cancer with ectopic adrenocorticotropin production.
    Clinical nuclear medicine, 2015, Volume: 40, Issue:1

    A 51-year-old man with a history of metastatic medullary thyroid cancer (MTC) presented with high adrenocorticotropin (ACTH) and urinary free cortisol levels. The diagnosis of ectopic ACTH production, a rare MTC complication, was established in this patient. PET/CT using the somatostatin analogue DOTA-(Tyr)-octreotate labeled with gallium (Ga-DOTATATE) was performed, showing positive radionuclide uptake in multiple MTC metastases. After this therapy with the novel somatostatin analogue, pasireotide was initiated after which urinary free cortisol and ACTH levels decreased. The present case thus illustrates a potential theranostic use of Ga-DOTATATE PET/CT in MTC.

    Topics: Adrenocorticotropic Hormone; Carcinoma, Neuroendocrine; Humans; Male; Middle Aged; Multimodal Imaging; Organometallic Compounds; Positron-Emission Tomography; Radiopharmaceuticals; Somatostatin; Thyroid Neoplasms; Tomography, X-Ray Computed

2015